Minerva Neurosciences (NERV) Projected to Post Earnings on Tuesday

Minerva Neurosciences (NASDAQ:NERV) is expected to be issuing its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, February 23, 2026 at 9:30 AM ET.

Minerva Neurosciences Stock Performance

Shares of NERV stock opened at $6.31 on Friday. Minerva Neurosciences has a 1 year low of $1.15 and a 1 year high of $12.46. The stock has a market cap of $273.03 million, a PE ratio of -3.41 and a beta of -0.22. The business’s fifty day moving average is $4.64 and its 200-day moving average is $3.58.

Analyst Ratings Changes

NERV has been the topic of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Minerva Neurosciences in a report on Monday, December 29th. Wall Street Zen cut shares of Minerva Neurosciences from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. Finally, HC Wainwright cut their target price on shares of Minerva Neurosciences from $5.00 to $4.00 and set a “neutral” rating for the company in a research note on Thursday, November 6th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average price target of $4.00.

Institutional Trading of Minerva Neurosciences

A number of hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC purchased a new position in shares of Minerva Neurosciences during the fourth quarter valued at $36,000. State Street Corp grew its stake in Minerva Neurosciences by 45.4% during the 4th quarter. State Street Corp now owns 24,019 shares of the biopharmaceutical company’s stock valued at $97,000 after acquiring an additional 7,500 shares in the last quarter. Millennium Management LLC acquired a new position in shares of Minerva Neurosciences in the 4th quarter valued at about $554,000. Renaissance Technologies LLC boosted its holdings in shares of Minerva Neurosciences by 28.1% during the fourth quarter. Renaissance Technologies LLC now owns 149,200 shares of the biopharmaceutical company’s stock worth $600,000 after purchasing an additional 32,700 shares during the period. Finally, Ally Bridge Group NY LLC purchased a new position in Minerva Neurosciences during the fourth quarter valued at approximately $6,655,000. Hedge funds and other institutional investors own 34.56% of the company’s stock.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.

The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.